Drug
Siltuximab
Siltuximab: highest development phase Phase 3, developed by Genmab, Recordati. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Genmab, Recordati
Trials
| Drug | Phase | Indication |
|---|---|---|
| Siltuximab NCT04616586 | Phase 3 | Acute Respiratory Distress Syndrome |
| Siltuximab NCT04975555 | Phase 2 | Cytokine Release Syndrome |
| Siltuximab NCT06679829 | Phase 2 | Multiple Myeloma |
| Siltuximab NCT05684692 | Phase 2 | Schwannomatosis |
| Siltuximab NCT04838860 | Phase 2 | Idiopathic Multicentric Castleman's Disease |
| Siltuximab NCT06447376 | Phase 1 | Non-Hodgkin Lymphoma |
Latest
No recent events.
Follow Siltuximab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.